Provides AI-embedded commercial and medical outsourcing services to global life sciences companies, particularly large pharmaceutical firms. Enterprise Commercial Solutions, which contributed 70.1% of segment revenue at ₹2,460.5 crore in FY26, handles sales, marketing and omnichannel engagement work for pharma clients. Enterprise Medical Solutions, contributing 26.5% at ₹929.8 crore, covers medical affairs, scientific content and clinical communications. The company serves 20 of the Top 20 global pharma companies and 80 of the Top 100 life sciences firms, with an active client base that grew from 73 to 91 in FY26 and reached 105 by Q1 FY27. Employee costs are the dominant input at 62.6% of revenue, reflecting a delivery model built on specialised healthcare and technology talent rather than physical inputs. The company reports 98.47% export revenue, operates across 58 countries and runs 5,167 employees, with revenue per employee at approximately $77,000. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Enterprise Commercial Solutions (70%), Enterprise Medical Solutions (27%), Others (3%). People-heavy, asset-light technology and services business serving global pharma
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 2,590 | 2,839 | 3,511 |
| EBITDA (ex other income) | 508 | 534 | 599 |
| margin % | 19.6 | 18.8 | 17.1 |
| Owners' profit | 345 | 407 | 401 |
| EPS, as reported (₹) | 15.19 | 17.15 | 16.72 |
| ROE % · ROCE % | 23.6 · 26.3 | 15.5 · 20.3 | 12.8 · 15.4 |
| Debt / equity (x) | 0.28 | 0.00 | 0.00 |
| Cash from operations | 508 | 442 | 651 |
| Capex | (11) | (30) | (44) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Profit before tax | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Net profit | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS (₹) | 3.84 | 4.59 | 4.91 | 4.86 | 4.26 | 4.29 | 3.32 | 4.84 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Enterprise Medical Solutions | 930 | 26.5 |
| Enterprise Commercial Solutions | 2,321 | 66.1 |
| Others | 120 | 3.4 |
| Brand Activation | 140 | 4.0 |
| Total, before eliminations | 3,510 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SYNGENE INTERNATIONAL LTD | 15,466 | 69.7 | 3.20 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Indegene consolidates two German subsidiaries via internal merger | strategic transactions | medium | — | — |
| 8 Sept 2026 · Indegene to meet Premji Invest on 11 September 2026 in Bengaluru | board shareholder meetings | low | — | — |
| 31 Aug 2026 · US court gives preliminary approval to Indegene Inc TCPA class action settlement | regulatory legal | high | — | — |
| 19 Aug 2026 · Indegene schedules investor and analyst meetings on 24-25 August | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Update on US class action settlement against Indegene subsidiary (max USD 4.72M) | regulatory legal | high | — | — |
| 17 Aug 2026 · Indegene 28th AGM: FY26 revenue up 23.6%, margin recovery to 19-20% guided | investor communications | low | — | — |
| 17 Aug 2026 · Indegene appoints Ms. Jill Mary De Simone as Independent Director | management changes | medium | — | — |
| 17 Aug 2026 · Indegene 28th AGM: All Resolutions Passed by Members | board shareholder meetings | low | — | — |
| 14 Aug 2026 · Indegene to meet Buoyant Capital on 19 August 2026 | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Indegene 28th AGM held on Aug 13, 2026 via video conferencing | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 16.7 |
| 6.5 |
| 7.5 |
| 11.3 |
| 13.9 |
| INDEGENE LIMITED ◆ | 13,959 | 34.7 | 4.45 | 20.4 | 12.8 | 14.9 | — | 19.1 |
| SUVEN LIFE SCIENCES LTD | 9,476 | — | 16.02 | — | (46.7) | (46.6) | (12.0) | (3504.9) |
| VIMTA LABS LIMITED | 2,819 | 22.8 | 8.22 | 31.1 | 8.0 | 11.0 | 8.4 | 38.2 |
| TAKE LIMITED | 261 | 20.5 | 8.40 | 54.5 | 35.0 | 14.2 | (41.2) | 3.5 |
| BILCARE LTD. | 219 | 6.2 | 2.95 | 11.8 | (23.3) | (3.9) | 3.3 | 15.7 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 34.7 | 31.2 | 37 of 68 | 46% |
| P/B | 4.5 | 5.2 | 27 of 57 | 54% |
| ROCE | 14.9 | 8.0 | 12 of 69 | 84% |
| ROE | 12.8 | 9.4 | 22 of 59 | 64% |
| Debt / Equity | 0.0 | 0.1 | 3 of 59 | 76% |
| EBITDA margin | 19.1 | 21.5 | 34 of 57 | 41% |
| Revenue growth | 39.7 | 20.2 | 13 of 57 | 79% |
| Profit growth | (0.2) | 11.4 | 37 of 55 | 33% |
| Market cap | 13959 | 261 | 13 of 71 | 83% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
